Icotrokinra Results Show Significant Skin Clearance in Patients With Difficult-To-Treat Scalp and Genital Psoriasis
May 10, 2025
May 10, 2025
RARITAN, New Jersey, May 10 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:
* * *
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at . . .
* * *
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at . . .